Omalizumab (Xolair) treatment of adults and adolescents (12 years of age and above) with chronic idiopathic urticaria
The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2015, 2015
|
| Series: | Common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | The objective of this systematic review was to assess the beneficial and harmful effects of omalizumab (OMA) for the treatment of chronic idiopathic urticaria (CIU) in adults and adolescents who remain symptomatic despite H1 antihistamine treatment |
|---|---|
| Physical Description: | 1 PDF file illustrations |